The current epidemiological status of infectious coryza and efficacy of PoulShot Coryza in specific pathogen-free chickens.
10.4142/jvs.2016.17.3.323
- Author:
Moo Sung HAN
1
;
Jong Nyeo KIM
;
Eun Ok JEON
;
Hae Rim LEE
;
Bon Sang KOO
;
Kyeong Cheol MIN
;
Seung Baek LEE
;
Yeon Ji BAE
;
Jong Suk MO
;
Sun Hyung CHO
;
Hye Sun JANG
;
In Pil MO
Author Information
1. Avian Disease Laboratory, College of Veterinary Medicine, Chungbuk National University, Cheongju 28644, Korea. moip@cbu.ac.kr
- Publication Type:Original Article
- Keywords:
Avibacterium paragallinarum;
infectious coryza;
infectious coryza vaccine;
serologic survey
- MeSH:
Agriculture;
Chickens*;
Chungcheongbuk-do;
Communicable Diseases;
Erythromycin;
Gentamicins;
Korea;
Lincomycin;
Multiplex Polymerase Chain Reaction;
Neomycin;
Ovum;
Oxytetracycline;
Polymerase Chain Reaction;
Poultry;
Serogroup;
Spectinomycin;
Tylosin
- From:Journal of Veterinary Science
2016;17(3):323-330
- CountryRepublic of Korea
- Language:English
-
Abstract:
Infectious coryza (IC) is an infectious disease caused by Avibacterium (Av.) paragallinarum. IC is known to cause economic losses in the poultry industry via decreased egg production in layers. Between 2012 and 2013, Av. paragallinarum was isolated from seven chicken farms by Chungbuk National University. We identified Av. paragallinarum, the causative pathogen of IC by polymerase chain reaction (PCR) and serovar serotype A, by multiplex PCR. Antibiotic sensitivity tests indicated that a few field-isolated strains showed susceptibility to erythromycin, gentamicin, lincomycin, neomycin, oxytetracycline, spectinomycin, and tylosin. A serological survey was conducted to evaluate the number of flocks that were positive for Av. paragallinarum by utilizing a HI test to determine the existence of serovar A. Serological surveys revealed high positivity rates of 86.4% in 2009, 78.9% in 2010, 70.0% in 2011, and 69.6% in 2012. We also challenged specific pathogen-free chickens with isolated domestic strains, ADL121286 and ADL121500, according to the measured efficacy of the commercial IC vaccine, PoulShot Coryza. We confirmed the effectiveness of the vaccine based on relief of clinical signs and a decreased re-isolation rate of ADL121500 strain. Our results indicate IC is currently prevalent in Korea, and that the commercial vaccine is effective at protecting against field strains.
